Allan Gobbs is the managing partner of ATEM Capital, a biotechnology venture firm based in New York. Additionally, he is a member of the Review Committee of the National Cancer Institute, a part of the National Institutes of Health (NIH).
Researchers say they have used CRISPR gene technology to engineer a bacteria that can help detect tumor DNA in the body before cancer appears